Target intelligence / Profile preview

Nicotinamide phosphoribosyltransferase (NAMPT) (NAMPT)

Target
NAMPT
Molecular classification
Enzyme, Cytokine, Adipokine
01

Overview

Nicotinamide phosphoribosyltransferase (NAMPT), also known as visfatin or pre-B-cell colony-enhancing factor (PBEF), is the rate-limiting enzyme in the mammalian nicotinamide adenine dinucleotide (NAD+) salvage pathway, converting nicotinamide to nicotinamide mononucleotide (UniProt P43490). It exists in two distinct forms: intracellular NAMPT (iNAMPT), which maintains the NAD+ pool required for mitochondrial function and DNA repair, and extracellular NAMPT (eNAMPT), which acts as a pro-inflammatory adipokine. NAMPT is frequently overexpressed in various malignancies, including colorectal, ovarian, and breast cancers, to support the high metabolic and DNA repair demands of tumor cells. Consequently, NAMPT is a significant therapeutic target in oncology, with small-molecule inhibitors like FK866 and KPT-9274 designed to induce metabolic collapse and apoptosis through NAD+ depletion. Beyond oncology, its role in inflammatory signaling links it to conditions such as rheumatoid arthritis and metabolic syndrome, though clinical development of inhibitors has been challenged by dose-limiting toxicities like thrombocytopenia.

Other names
VisfatinPre-B-cell colony-enhancing factor 1PBEF1PBEF
02

Mechanism of action

Competitive or non-competitive inhibition of the NAMPT enzyme, which prevents the conversion of nicotinamide to nicotinamide mononucleotide, thereby depleting cellular NAD+ pools and inducing metabolic collapse.

03

Biological functions

NAD+ biosynthesisMetabolic regulationInflammatory signalingCell proliferationDNA repair
04

Disease associations

CancerInflammationRheumatoid arthritisMetabolic syndromeType 2 diabetesCardiovascular disease
05

Safety considerations

Dose-limiting thrombocytopeniaGastrointestinal toxicityPotential retinal toxicityLymphopeniaSystemic metabolic interference
06

Interacting drugs

FK866 (Daporinad)

4 more in the full profile.

07

Biomarkers

Circulating eNAMPT levelsIntracellular NAD+ concentrationNAMPT protein expression in tumor tissueNAMPT mRNA expression levels

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Nicotinamide phosphoribosyltransferase (NAMPT) (NAMPT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinamide phosphoribosyltransferase (NAMPT) (NAMPT).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call